WAC 246-650-020. Performance of screening tests

(1) Hospitals and other providers of birth and delivery services or neonatal care to infants shall: (a) Inform parents or guardians, by providing a departmental information pamphlet or by other means, of: (i) The purpose of screening newborns for congenital disorders; (ii) Disorders of concern as listed in WAC 246-650-020(2); (iii) The requirement for newborn screening; (iv) The legal right of parents or guardians to refuse testing because of religious tenets or practices as specified in RCW 70.83.020 ; and (v) The specimen storage, retention and access requirements specified in WAC 246-650-050 . (b) Obtain a blood specimen for laboratory testing as specified by the department from each newborn no later than forty-eight hours following birth. (c) Use department-approved newborn screening specimen/information forms and directions for obtaining specimens. (d) Enter all identifying and related information required on the newborn screening specimen/information form following directions of the department. (e) In the event a parent or guardian refuses to allow newborn screening, obtain signatures from parents or guardians on the newborn screening specimen/information form. (f) Forward the newborn screening specimen/information form with dried blood spots or signed refusal to the Washington state public health laboratory so that it will be received no later than seventy-two hours following collection of the specimen, excluding any day that the state laboratory is closed. (2) Upon receipt of specimens, the department shall: (a) Record the time and date of receipt; (b) Perform appropriate screening tests for: (i) Amino acid disorders; (ii) Biotinidase deficiency; (iii) Congenital hypothyroidism; (iv) Congenital adrenal hyperplasia; (v) Cystic fibrosis; (vi) Fatty acid oxidation disorders; (vii) Galactosemia; (viii) Guanidinoacetate Methyltransferase (GAMT) deficiency; (ix) Hemoglobinopathies; (x) Mucopolysaccharidosis type I (MPS-I); (xi) Organic acid disorders; (xii) Pompe disease; (xiii) Severe combined immunodeficiency (SCID); (xiv) Spinal muscular atrophy (SMA); (xv) Urea cycle disorders; (xvi) X-linked adrenoleukodystrophy (X-ALD). (c) Report significant screening test results to the infant's attending health care provider or parent or guardian if an attending health care provider cannot be identified; and (d) Offer diagnostic and treatment resources to health care providers attending infants with significant screening test results within limits determined by the department.